Anti-Tap63 [TAp63-4.1]

Cat. #162057

Anti-Tap63 [TAp63-4.1]

Cat. #: 162057

Sub-type: Primary antibody

Target: transactivation domain of tumour protein p63

Class: Monoclonal

Reactivity: Human ; mouse ; rat

Host: Mouse


This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.


Institute: Moravian Biotechnology

Tool Details
Target Details

Tool Details


  • Name: Anti-Tap63 [TAp63-4.1]
  • Clone: TAp63-4.1
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 76 kD
  • Reactivity: Human ; mouse ; rat
  • Host: Mouse
  • Description: Antibody created to detect the TA isoform of p63 (TAp63) with tumour suppressor role and differentiate from the deltaN (deltaNp63) isoforms of the same protein. Binding specificity: epitope mapping using phage disply identified the epitope LSDPxW for all clones.
  • Immunogen: Recombinant human TAp63delta
  • Isotype: IgG2a kappa
  • Production details: B cell donor: Splenocytes from mouse immunised with recombinant TAp63? , Fusion partner: SP2

Target Details

  • Target: transactivation domain of tumour protein p63
  • Molecular weight: 76 kD
  • Target background: p63 is a transcription factor of the p53 gene family, encoded by the TP63 gene located at chromosome 3q28. p63 exists as N-terminal isoforms that either contain (TAp63) or lack (deltaNp63) the p53-like transactivation domain at the N-terminus. C-terminal isoforms are produced by alternative splicing of 3' exons. TAp63 is involved in germ cell maintenance and myocyte differentiation, and is expressed in some lymphocytes and lymphomas/leukaemias.
  • Epitope sequence: LSDPxW sequence of tumour protein p63 (TA isoform)


  • Format: Liquid


  • Orzol et al. 2016. Tumour Biol. Aug:37(8):10133-40. PMID: 26825981
  • Galoczova et al. 2021. Virchows Arch. Apr:478(4):627-636. PMID: 33037932
  • Pokorna et al. 2022. Front Oncol. Jul 14:12:924354. PMID: 35912167